Cargando…
Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital
Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect on hospitalization rates. Methods: For this retro...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956015/ https://www.ncbi.nlm.nih.gov/pubmed/36826353 http://dx.doi.org/10.3390/idr15010013 |
_version_ | 1784894489004867584 |
---|---|
author | Pannier, Judith Nass, Norbert Yaakoub, Mohamad-Kamal Stelzner, Florian Michael Maria Veit, Susann Kalomoiri, Margarita Yassine, Mahdi Behre, Gerhard |
author_facet | Pannier, Judith Nass, Norbert Yaakoub, Mohamad-Kamal Stelzner, Florian Michael Maria Veit, Susann Kalomoiri, Margarita Yassine, Mahdi Behre, Gerhard |
author_sort | Pannier, Judith |
collection | PubMed |
description | Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect on hospitalization rates. Methods: For this retrospective, observational study, clinical data were collected in 2021 from outpatients (402) as well as hospitalized patients (350) receiving monoclonal antibodies Bamlanivimab, Casirivimab/Imdevimab or Etesevimab/Bamlanivimab. These data were compared with data from a control group of patients not receiving antibodies because admission to the hospital was too late for this therapy. Results: Both groups showed a comparable spectrum of risk factors. Due to the late hospitalization of control patients, a higher frequency of severe symptoms, such as fever, dyspnea, syncope and lower viral load, were observed. CRP and leukocytes counts were also higher in the untreated group. Most importantly, hospitalization time was significantly shorter and the number of deaths was also lower in the treated group. Conclusions: Apparently, the application of anti-SARS-CoV-2 antibodies reduced the work load of our hospital as shown by the shorter hospitalization time and lower number of COVID-19-related deaths. |
format | Online Article Text |
id | pubmed-9956015 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99560152023-02-25 Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital Pannier, Judith Nass, Norbert Yaakoub, Mohamad-Kamal Stelzner, Florian Michael Maria Veit, Susann Kalomoiri, Margarita Yassine, Mahdi Behre, Gerhard Infect Dis Rep Communication Background: Monoclonal antibodies represent one option for treatment of COVID-19 early after infection. Although large clinical trials have been successfully conducted, real world data are needed to obtain a realistic assessment of the assumed effect on hospitalization rates. Methods: For this retrospective, observational study, clinical data were collected in 2021 from outpatients (402) as well as hospitalized patients (350) receiving monoclonal antibodies Bamlanivimab, Casirivimab/Imdevimab or Etesevimab/Bamlanivimab. These data were compared with data from a control group of patients not receiving antibodies because admission to the hospital was too late for this therapy. Results: Both groups showed a comparable spectrum of risk factors. Due to the late hospitalization of control patients, a higher frequency of severe symptoms, such as fever, dyspnea, syncope and lower viral load, were observed. CRP and leukocytes counts were also higher in the untreated group. Most importantly, hospitalization time was significantly shorter and the number of deaths was also lower in the treated group. Conclusions: Apparently, the application of anti-SARS-CoV-2 antibodies reduced the work load of our hospital as shown by the shorter hospitalization time and lower number of COVID-19-related deaths. MDPI 2023-02-20 /pmc/articles/PMC9956015/ /pubmed/36826353 http://dx.doi.org/10.3390/idr15010013 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Pannier, Judith Nass, Norbert Yaakoub, Mohamad-Kamal Stelzner, Florian Michael Maria Veit, Susann Kalomoiri, Margarita Yassine, Mahdi Behre, Gerhard Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital |
title | Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital |
title_full | Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital |
title_fullStr | Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital |
title_full_unstemmed | Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital |
title_short | Monoclonal Antibody Therapy for COVID-19: A Retrospective Observational Study at a Regional Hospital |
title_sort | monoclonal antibody therapy for covid-19: a retrospective observational study at a regional hospital |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9956015/ https://www.ncbi.nlm.nih.gov/pubmed/36826353 http://dx.doi.org/10.3390/idr15010013 |
work_keys_str_mv | AT pannierjudith monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital AT nassnorbert monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital AT yaakoubmohamadkamal monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital AT stelznerflorianmichaelmaria monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital AT veitsusann monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital AT kalomoirimargarita monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital AT yassinemahdi monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital AT behregerhard monoclonalantibodytherapyforcovid19aretrospectiveobservationalstudyataregionalhospital |